|
Sign In to gain access to subscriptions and/or personal tools.
|
The effects of candesartan on vascular responses to angiotensin II and norepinephrine in normal volunteers
Diane Tran
Department of Clinical Pharmacology, St. George Hospital, UNSW
Stephen Phoon
Department of Aged Care St. George Hospital, UNSW, Kogarah, NSW 2210, Australia
Laurence Howes
Department of Clinical Pharmacology, St. George Hospital, UNSW, l.howes@ unsw.edu.au
The effects of chronic administration of candesartan, 16 mg once-daily, to normal volunteers on cardiovascular responses to angiotensin II (Ang II) and norepinephrine (NE) were examined.
Fifteen healthy, non-smoking volunteers participated in a randomised, double-blind crossover study of two weeks of candesartan therapy, compared with two weeks of placebo. Blood pressure (BP) responses were measured to increasing infusion rates of intravenous Ang II and NE, along with forearm blood flow (FBF) responses into intra-brachial arterial Ang II, 2 and 24 hours after the last dose of candesartan or placebo. FBF responses to intra-brachial arterial NE were recorded approximately 2 hours following the final dose.
Systolic and diastolic BP responses to intravenous infusions of Ang II during candesartan treatment were completely suppressed and significantly lower than during placebo treatment, 2 hours (candesartan 96±10/55±8 mmHg; placebo 105±5/64±8 mmHg) and 24 hours (candesartan 94±8/54±8 mmHg; placebo 103±7/64±7 mmHg) following the last dose. In contrast, FBF responses to intra-brachial arterial Ang II were significantly suppressed by candesartan compared with placebo in a subgroup of subjects 2 hours following the last dose (n=9), but not 24 hours after the last dose (n=8). FBF responses to NE were also suppressed by candesartan treatment 2 hours following the last dose, while BP responses to intravenous NE were unaltered. Chronic candesartan therapy, 16 mg once-daily effectively suppresses pressor responses to Ang II over the duration of the dosing interval.
Key Words: candesartan cilexetil • vascular responsiveness • angiotensin II • norepinephrine
References
- Timmermans Pbmwm, Wong PC, Chiu AT, Herblin WF Non-peptide angiotensin II receptor antagonists. TIPS 1991;12:55-62.[Medline]
[Order article via Infotrieve]
- Chung O., Stoll M., UngerT. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Pressure 1996;5(suppl 2):47-52.
- Mancia G., Dell'Ovo R., Turri C., Grassi G. Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol 1999;84(10A):28S-34S.[Web of Science][Medline]
[Order article via Infotrieve]
- Zuschke CA, Keys I., Munger MA et al. Candesartan cilexetil: comparison of once daily versus twice daily administration for systemic hypertension. Clin Ther 1999;21(3):464-74.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Delacretaz E., Nussberger J.,Biollaz J., Waeber B., Brunner HR Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995;25:14-21.[Abstract/Free Full Text]
- Belz CG, Fuchs B., Malerczyk C., Magin SG, Roll S., Mutschler E. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997;11(suppl 2):S45-S47.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ruiz-Gayo M., Somoza B., Fernandez-Alfonso MS, Gonzalez C. Chronic losartan treatment decreases angiotensin II facilitation of noradrenaline release in the caudal artery of spontaneously hypertensive rats. Life Sci 2000;67(26):3153-62.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Harada K., KawaguchiA, Ohmori M., FujimuraA. Influence of losartan on alpha-adrenoreceptor mediated vasoconstrictor responses in humans. J Cardiovasc Pharmacol 2000;36(1):45-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 3,
199-203 (2001)
DOI: 10.3317/jraas.2001.028
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Schindler
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET
Therapeutic Advances in Cardiovascular Disease,
August 1, 2008;
2(4):
233 - 248.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Thai, J. Wollmuth, S. Goldman, and M. Gaballa
Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor
J. Pharmacol. Exp. Ther.,
December 1, 2003;
307(3):
1171 - 1178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
